Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hyperion Therapeutics Inc to acquire Andromeda Biotech Ltd from Clal Biotechnology Industries Ltd


Thursday, 24 Apr 2014 03:32am EDT 

Hyperion Therapeutics Inc:Enters into definitive agreement under which it will acquire Andromeda Biotech Ltd, Israel-based subsidiary of Clal Biotechnology Industries Ltd.Hyperion will pay $12.5 mln in cash, less adjustments for expenses incurred in connection with the transaction and 312,869 shares of Hyperion common stock (valued at about $7.85 mln).Andromeda will become wholly owned subsidiary of Hyperion. 

Company Quote

24.3
-0.13 -0.53%
31 Oct 2014